Trials / Completed
CompletedNCT00479219
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSI-953 | |
| OTHER | Placebo |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2007-05-28
- Last updated
- 2008-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00479219. Inclusion in this directory is not an endorsement.